Eukaryotic Cell Patents (Class 424/93.21)
  • Patent number: 11905336
    Abstract: Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: February 20, 2024
    Assignee: Lung Therapeutics, Inc.
    Inventors: Dale Christensen, John J. Koleng
  • Patent number: 11905328
    Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: February 20, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Martin Hofmann, Felix Unverdorben, Sebastian Bunk, Dominik Maurer
  • Patent number: 11905514
    Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: February 20, 2024
    Assignee: GLAXOSMITHKLINE BIOLOGICAL SA
    Inventor: Andrew Geall
  • Patent number: 11891608
    Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus, the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: February 6, 2024
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Andrew Geall
  • Patent number: 11883433
    Abstract: Provided is an anti-mesothelin chimeric antigen receptor that specifically binds to mesothelin. The anti-mesothelin chimeric antigen receptor according to an aspect exhibits a specific binding ability for mesothelin, and thus, may be useful for preventing or treating cancer in which mesothelin is overexpressed.
    Type: Grant
    Filed: May 25, 2022
    Date of Patent: January 30, 2024
    Assignee: CELLENGENE INC.
    Inventors: Jae Hyung An, Na Kyung Han
  • Patent number: 11866731
    Abstract: Provided are modified immune cells including tumor infiltrating lymphocyte (TIL) or B cells, a composition comprising the immune cells, and a method of treating neoplastic or cancer conditions comprising administering to a subject the immune cells.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: January 9, 2024
    Assignee: CHINEO MEDICAL TECHNOLOGY CO., LTD
    Inventor: Weiyue Gu
  • Patent number: 11851491
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs) having specificity for one or more tumor cell associated antigens, T cells engineered to express one or more TFP, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: December 26, 2023
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Robert Hofmeister
  • Patent number: 11850288
    Abstract: A gene and cell therapy using a cell fusion technology is proposed. Cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: December 26, 2023
    Assignee: CURAMYS INC.
    Inventors: Jung-Joon Sung, Seung-Yong Seong, Hee-Woo Lee, Ki Yoon Kim
  • Patent number: 11851653
    Abstract: The present application provides materials and methods for treating a patient with Alpha-1 antitrypsin deficiency (AATD) both ex vivo and in vivo. In addition, the present application provides materials and methods for editing the SERPINA1 gene in a cell by genome editing.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: December 26, 2023
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Chad Albert Cowan, Roman Lvovitch Bogorad, Jeffrey Li, Ante Sven Lundberg, Matthias Johannes John, Jeffrey William Stebbins, Thao Thi Nguyen
  • Patent number: 11851660
    Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: December 26, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Andrew Geall
  • Patent number: 11845965
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: December 19, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, Edward J. Rebar
  • Patent number: 11845925
    Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: December 19, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Andrew Geall
  • Patent number: 11827705
    Abstract: The present invention includes compositions and methods for an HLA-A2 specific chimeric antigen receptor (CAR). In certain embodiments the HLA-A2 specific CAR is expressed on a T regulatory cell. In certain embodiments, the HLA-A2 specific CAR protects transplanted tissue from rejection.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: November 28, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James L. Riley, Gavin Ellis
  • Patent number: 11815514
    Abstract: Provided are methods, kits and compositions related to toxicity associated with administration of cell therapy for the treatment of diseases or conditions, e.g., cancer, including methods for use in predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a parameter of a biomarker or individually a parameter of each biomarker in a panel of biomarkers, such as a concentration, amount or activity, and comparing the detected parameter to a reference value for the parameter to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: November 14, 2023
    Assignees: Juno Therapeutics, Inc., Fred Hutchinson Cancer Research Center
    Inventors: He Li, Mark J. Gilbert, David Maloney, Stanley R. Riddell, Cameron J. Turtle
  • Patent number: 11795474
    Abstract: The invention relates to retroviral producer cell comprising nucleic acid sequences encoding: gag and pol proteins; envelope protein or a functional substitute thereof; amplifiable selection marker; and the RNA genome of the retroviral vector particle, wherein said nucleic acid sequences are all integrated at a single locus within the retroviral producer cell genome. The invention also relates to nucleic acid vectors comprising a non-mammalian origin of replication and the ability to hold at least 25 kilobases (kb) of DNA, characterized in that said nucleic acid vector comprises retroviral nucleic acid sequences encoding: gag and pol proteins, and an env protein or a functional substitute thereof. The nucleic acid vector additionally comprises nucleic acid sequences encoding an amplifiable selection marker. The invention also relates to uses and methods using said nucleic acid vector in order to produce stable retroviral packaging and producer cell lines.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: October 24, 2023
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventor: Conrad Vink
  • Patent number: 11793888
    Abstract: Nucleases and methods of using these nucleases for expressing an antibody from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: October 24, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Michael C. Holmes, Brigit E. Riley
  • Patent number: 11773395
    Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: October 3, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Andrew Geall
  • Patent number: 11732240
    Abstract: The present invention relates to a composition for inducing direct conversion from a somatic cell into one or more kinds selected from the group consisting of an induced Hepatic stem cell (iHSC), a hepatocyte, and a cholangiocyte, and a method of direct conversion of a somatic cell into one or more kinds selected from the group consisting of an induced Hepatic stem cell, a hepatocyte, and a cholangiocyte.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: August 22, 2023
    Assignee: UNIST (ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY)
    Inventors: Jeong Beom Kim, Myung Rae Park, Man Sze Wong
  • Patent number: 11717579
    Abstract: The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: August 8, 2023
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, UNIVERSITY OF WASHINGTON
    Inventors: Michel Sadelain, Isabelle Riviere, Jorge Mansilla-Soto, Xiuyan Wang, George Stamatoyannopoulos, John Stamatoyannopoulos, Mingdong Liu
  • Patent number: 11707488
    Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects against various diseases, a novel pharmaceutical composition containing these mesenchymal stem cells, and a method for preparing the same. The present invention relates to ROR1-positive mesenchymal stem cells. The ROR1-positive mesenchymal stem cells are preferably positive for CD29, CD73, CD90, CD105 and CD166 and are derived from umbilical cord or adipose tissue.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: July 25, 2023
    Assignee: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Yoshifumi Ikeyama, Hiroyuki Nishida, Tomohiro Tsuda, Eiko Uno, Masayo Yumoto, Kazuma Suda, Mihoko Yoshino, Xuan Trung Ngo
  • Patent number: 11685909
    Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: June 27, 2023
    Assignee: The Regents of the University of California
    Inventors: Jennifer A. Doudna, Basem Al-Shayeb, Jillian F. Banfield, Patrick Pausch
  • Patent number: 11649436
    Abstract: The present invention relates to an exosome for stimulating T cells and the pharmaceutical use thereof. Immune exosomes secreted from artificial antigen-presenting cells which express HLA, CD32, and co-stimulatory molecules CD32, CD80, CD83, and 4-1BBL are used to stimulate naive CD8+ T cells whereby preventive and therapeutic effects on tumors, pathogen infections, or autoimmune diseases can be provided.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: May 16, 2023
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Tai Gyu Kim, Hyun Jung Sohn, Su Eon Kim
  • Patent number: 11649431
    Abstract: Provided are cortical interneurons and other neuronal cells and in vitro methods for producing such cortical interneurons and other neuronal cells by the directed differentiation of stem cells and neuronal progenitor cells. The present disclosure relates to novel methods of in vitro differentiation of stem cells and neural progenitor cells to produce several type neuronal cells and their precursor cells, including cortical interneurons, hypothalamic neurons and pre-optic cholinergic neurons. The present disclose describes the derivation of these cells via inhibiting SMAD and Wnt signaling pathways and activating SHH signaling pathway. The present disclosure relates to the novel discovery that the timing and duration of SHH activation can be harnessed to direct controlled differentiation of neural progenitor cells into either cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: May 16, 2023
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, CORNELL UNIVERSITY
    Inventors: Lorenz Studer, Asif M. Maroof, Stewart Anderson
  • Patent number: 11634732
    Abstract: In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: April 25, 2023
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Daniel P. Dever, Rasmus O. Bak, Ayal Hendel, Waracharee Srifa, Matthew H. Porteus
  • Patent number: 11613735
    Abstract: A method for inducing reprogramming of a cell of a first type which is not a non-hepatocyte (non-hepatocyte cell), into a cell with functional hepatic drug metabolizing and transporting capabilities, is disclosed. The non-hepatocyte is induced to express or overexpress hepatic fate conversion and maturation factors, cultured in somatic cell culture medium, hepatocyte cell culture medium and hepatocyte maturation medium for a sufficient period of time to convert the non-hepatocyte cell into a cell with hepatocyte-like properties. The iHeps induced according to the methods disclosed herein are functional induced hepatocytes (iHeps) in that they express I and II drug-metabolizing enzymes and phase III drug transporters and show superior drug metabolizing activity compared to iHeps obtained by prior art methods. The iHeps thus provide a cell resource for pharmaceutical applications.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: March 28, 2023
    Assignees: BeiHao Stem Cell and Regenerative Medicine Translational Research Institute, Peking University, Beijing Vitalstar Biotechnology Co., Ltd.
    Inventors: Hongkui Deng, Yuanyuan Du, Yan Shi, Jun Jia, Jinlin Wang, Chengang Xiang, Nan Song, Jun Xu, Ming Yin
  • Patent number: 11607427
    Abstract: A method of radiation-free hematopoietic stem cell (HSC) transplantation comprises administering to a mammalian subject one or two doses of 2 to 10 mg/kg body weight of a purine base analog, such as 6TG as a pre-conditioning step. The method further comprises engrafting into the subject hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient donor HSCs within 48 to 72 hours of the pre-conditioning step; and administering to the subject about 1 to 5 mg/kg of the purine base analog every two to four days for two to eight weeks following the engrafting step. The method is performed in the absence of pre-conditioning via radiation. The subject is therefore not treated with myeloablative radiation in preparation for transplantation, and thus the subject is free of myeloablative radiation-induced toxicity.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: March 21, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Noriyuki Kasahara, Robert H. Schiestl, Katrin Hacke, Akos Szakmary, Gay M. Crooks
  • Patent number: 11596700
    Abstract: The present application relates to a non-human mammal model of a human neurodegenerative disorder, methods of producing the non-human mammal model, and methods of using the non-human mammal model to identify agents suitable for treating a neurodegenerative disorder. The present application also relates to methods of treating neurodegenerative disorders and restoring normal brain interstitial potassium levels.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: March 7, 2023
    Assignee: UNIVERSITY OF ROCHESTER
    Inventor: Steven A. Goldman
  • Patent number: 11579141
    Abstract: The present invention relates to an in vitro method for identifying a skin wound in an individual as being a non-healing skin wound or healing skin wound, in vitro methods for monitoring the healing of a skin wound in an individual, methods for screening for compounds suitable for modulating skin wound healing, as well as kits related thereto.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: February 14, 2023
    Assignee: AKRIBES BIOMEDICAL GMBH
    Inventors: Barbara Wolff-Winiski, Anton Stütz, Petra Dörfler
  • Patent number: 11564942
    Abstract: Disclosed herein are methods for generating universal MHC/HLA-compatible hematopoietic progenitor cells and methods for generating custom patient-specific MHC/HLA-compatible hematopoietic progenitor cells. Compositions comprising the universal and custom hematopoietic progenitor cells and therapeutic applications thereof are also disclosed.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: January 31, 2023
    Assignees: The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: Michael K. Mansour, David B. Sykes, David T. Scadden
  • Patent number: 11560402
    Abstract: The invention relates to a method for the cleavage of a solid phase-bound polypeptide from the solid phase, the method comprising contacting the solid phase, to which the polypeptide is bound, with a composition consisting essentially of trifluoroacetic acid and 1,2-ethanedithiol, at a temperature in the range of about 23° C. to about 29° C.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: January 24, 2023
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Wolfgang Fiedler, Norbert Pleuss, Bernd Henkel, Manfred Gerken
  • Patent number: 11530252
    Abstract: Described herein is a chimeric antigen receptor (CAR) platform with the ability to (a) serve as an ON/OFF switch (with the ability for tenability/titrability), (b) sense multiple antigens and perform logic computations, and/or (c) independently regulate multiple signaling pathways. The compositions provided herein permit the degree of control and discrimination necessary to optimize CAR T cell therapy. Also described herein are cells comprising such compositions and the use of these compositions and/or cells in the treatment of cancer.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: December 20, 2022
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Wilson W. Wong, Jang Hwan Cho
  • Patent number: 11525004
    Abstract: Disclosed are compositions and methods for targeted treatment of CD123-expressing cancers. In particular, recombinant antibodies are disclosed that are able to engage T-cells to destroy CD123-expressing malignant cells.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: December 13, 2022
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventor: Marco L. Davila
  • Patent number: 11517530
    Abstract: Provided herein are extracellular vesicle (EV) (a.k.a. exosome) compositions for specifically targeting the delivery of a therapeutic agent to particular cells and/or tissues in a subject, as well as methods of making and methods of using said compositions. The compositions and methods disclosed herein are useful for targeted drug delivery in the treatment of diseases in which a cell surface receptor is overexpressed, such as, for example, cancer.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: December 6, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jing-Hung Wang, Alexis Forterre, A. C. Matin, Alain Delcayre
  • Patent number: 11517590
    Abstract: In order to improve the efficiency of gene introduction in CAR therapy employing a transposon method, provided is a method for preparing genetically-modified T cells expressing chimeric antigen receptor, comprising: (1) a step of preparing non-proliferative cells which are obtained by stimulating a group of cells comprising T cells using an anti-CD3 antibody and an anti-CD28 antibody followed by a treatment for causing the cells to lose their proliferation capability; (2) a step of obtaining genetically-modified T cells into which a target antigen-specific chimeric antigen receptor gene has been introduced using a transposon method; (3) a step of mixing the non-proliferative cells prepared by step (1) with the genetically-modified T cells obtained by step (2), and co-culturing the mixed cells while stimulating the mixed cells using an anti-CD3 antibody and anti-CD28 antibody; and (4) a step of collecting the cells after culture.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: December 6, 2022
    Assignee: NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM
    Inventors: Nobuhiro Nishio, Yozo Nakazawa, Miyuki Tanaka, Daisuke Morita, Yoshiyuki Takahashi
  • Patent number: 11512139
    Abstract: The present invention provides a chimeric antigen receptor (CAR), comprising an extracellular part, at least one intracellular signaling domain, and at least one transmembrane domain, wherein the extracellular part of said CAR comprises a) at least one antigen binding domain, and b) at least one cytokine receptor activating or blocking domain. The invention also provides isolated nucleic acid molecule(s) encoding for the said CAR, a cell comprising said nucleic acid molecule(s), a cell expressing said CAR and therapeutic uses of said CAR.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: November 29, 2022
    Assignee: Miltenyi Biotec B.V. & Co. KG
    Inventors: Hinrich Abken, Andreas Hombach
  • Patent number: 11497773
    Abstract: A population of genetically engineered T cells, comprising a disrupted Reg1 gene and/or a disrupted TGFBRII gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; and (c) reduced T cell exhaustion, (d) enhanced cytotoxicity activity, (e) resistant to inhibitory effects induced by TGF-b, and (f) resistant to inhibitory effects by fibroblasts and/or inhibitory factors secreted thereby, as compared to non-engineered T cell counterparts.
    Type: Grant
    Filed: October 4, 2021
    Date of Patent: November 15, 2022
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Mary-Lee Dequeant, Demetrios Kalaitzidis, Mohammed Ghonime
  • Patent number: 11497791
    Abstract: Described herein are compositions and methods of using placental stem cell recruiting factors, more specifically, isolated placental stem cell recruiting factors. In one embodiment, isolated placental stem cell recruiting factors are delivered to a site such as a diseased or injured organ and/or body part in an amount sufficient to recruit stem cells to the site.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: November 15, 2022
    Assignee: MiMedx Group, Inc.
    Inventors: Thomas J. Koob, Rebeccah J. C. Brown
  • Patent number: 11473105
    Abstract: The invention provides a bidirectional hCMV-CAG4 promoter and recombinant vectors and recombinant virus comprising the bidirectional hCMV-CAG4 promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such recombinant vectors and recombinant virus.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: October 18, 2022
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Kerstin Wunderlich, Jort Vellinga
  • Patent number: 11471487
    Abstract: The present invention includes a method for expanding a population of electroporated T cells. The method includes electroporating a population of cells comprising T cells with mRNA encoding a chimeric membrane protein comprising an antigen binding domain to a molecule and an intracellular domain of a co-stimulatory molecule, wherein the cultured T cells expand at least 10 fold. The invention further includes an expanded population of T cells, compositions comprising the cells and methods of treatment.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: October 18, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Xiaojun Liu, Carl H. June
  • Patent number: 11471420
    Abstract: Disclosed is a nanoparticle comprising an inner core comprising a virus; and an outer surface comprising a cellular membrane derived from a cell, and process of making thereof. The virus is an oncolytic virus and cellular membrane is derived from for example red blood cells.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: October 18, 2022
    Assignee: Coastar Therapeutics Inc.
    Inventor: Eddie Yocon Chung
  • Patent number: 11471491
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Grant
    Filed: October 1, 2021
    Date of Patent: October 18, 2022
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Patent number: 11471453
    Abstract: A method for modulating an immune response by activating or inhibiting dopaminergic neurons in the Ventral Tegmental Area (VTA) is provided. Modulation is achieved by modulating the activity, the abundance or both of: a natural killer cell, a CD8 T-cell, a CD4 T-cell, a B-cell, a dendritic cell, a macrophage, a granulocyte, or their combination.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: October 18, 2022
    Assignees: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED, HEALTH CORPORATION - RAMBAM
    Inventors: Asya Rolls, Tamar Ben Shannan, Hilla Azulay-Debbie, Fahed Hakim, Maya Schiller, Shai Shen-Orr, Elina Starosvetsky
  • Patent number: 11464806
    Abstract: A method of treating a tumor in a subject including administering a genetically modified mesenchymal stem cell (MSC), wherein the MSC includes one or more exogenous nucleic acid molecule(s), wherein the one or more exogenous nucleic acid molecule(s) includes one or more regions encoding two or more immune response-stimulating cytokines operably linked to one or more promoters or promoter/enhancer combinations, wherein the two or more immune response-stimulating cytokines include at least IL-7, and at least one of IL-12 or IL-21.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: October 11, 2022
    Assignee: JUNCTUCELL BIOMED MANUFACTURING GMBH
    Inventors: Christine Günther, Stefanos Theoharis, Felix Hermann, Ralf Huss
  • Patent number: 11459567
    Abstract: The present invention generally relates to the field of molecular biology and RNA interference (RNAi). More specifically, the present invention relates to specific siRNA molecules, compositions and uses thereof, as well as methods of treating cancer and methods of inhibiting cancer cell proliferation, particularly methods of treating breast cancer. Yet more particularly, the methods of the present invention are methods for inhibiting growth of triple negative breast cancer (TNBC). In a preferred embodiment, the invention provides specific siRNA molecules, comprising a sequence selected from SEQ ID NO: 1 and SEQ ID NO: 2, and from any other sequence having a sequence identity greater than 90% between the siRNA and the portion of the target gene. Such siRNA molecules are suitable for the treatment of breast cancer, particularly, TNBC.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: October 4, 2022
    Inventor: Patricia Virginia Elizalde
  • Patent number: 11458168
    Abstract: Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: October 4, 2022
    Assignee: Baylor College of Medicine
    Inventors: Leonid S. Metelitsa, Amy N. Courtney, Gengwen Tian
  • Patent number: 11446331
    Abstract: The present invention is directed to wound healing scaffolds cografted with a population of stem cells, wherein the population of stem cells are ABCB5+ stem cells. The scaffolds are, for instance, collagen glycosaminoglycan scaffolds.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: September 20, 2022
    Assignees: The Brigham and Women's Hospital, Inc., Children's Medical Center Corporation, The United States Government as Represented by the Department of Veterans Affairs
    Inventors: Markus H. Frank, Natasha Y. Frank, Dennis P. Orgill, George F. Murphy
  • Patent number: 11446249
    Abstract: Combining viral vector with surfactant preserves vector infectivity, and surfactant provided an unexpected benefit by protecting viral vector from damage due to transient elevated temperature.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: September 20, 2022
    Assignee: Trizell Ltd.
    Inventors: Minna Hassinen, Robert Shaw, Nigel Parker
  • Patent number: 11434505
    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: September 6, 2022
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Alireza Rezania, Rebeca Ramos-Zayas
  • Patent number: 11413357
    Abstract: The present invention relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as SMA and ALS as well as Pompe disease and lysosomal storage disorders. It is disclosed that administration of a non-ionic, low-osmolar contrast agent, together with a rAAV9 vector for the expression of Survival Motor Neuron protein, improves the survival of SMN mutant mice as compared to the administration of the expression vector alone.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: August 16, 2022
    Assignees: NATIONWIDE CHILDREN'S HOSPITAL, OHIO STATE INNOVATION FOUNDATION
    Inventors: Brian K. Kaspar, Arthur Burghes, Paul Porensky
  • Patent number: 11396551
    Abstract: The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: July 26, 2022
    Assignee: Pfizer Inc.
    Inventors: Surabhi Srivatsa Srinivasan, Niranjana Aditi Nagarajan, Siler Panowski, Yoon Park, Tao Sai, Barbra Johnson Sasu, Thomas John Van Blarcom, Mathilde Brunnhilde Dusseaux, Roman Ariel Galetto